Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1339-1350

  Schaaf, C ^a   Shan, B ^a   Buchfelder, M ^b   Losa, M ^c   Kreutzer, J ^d   Rachinger, W ^e   Stalla, G K ^a   Schilling, T ^f   Arzt, E ^g,h   Perone, M J ^g,h   Renner, U ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Hospitale San Raffaele   (Italy)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^h INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; CASPASE 3; CELL CYCLE PROTEIN; CURCUMIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LIPOCORTIN 5; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN GH3; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CURCUMA LONGA; DNA FRAGMENTATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, NUDE; PITUITARY HORMONES; PITUITARY NEOPLASMS; RATS;

EID: 72549087782     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0129     Document Type: Article

References (36)

1. Aggarwal BB, Sundaram C, Malani N & Ichikawa H 2007 Curcumin: the Indian solid gold. Advances in Experimental Medicine and Biology 595 1-75.
2. Anand P, Kunnumakkara AB, Newman RA & Aggarwal BB 2007 Bioavailability of curcumin: problems and promises. Molecular Pharmacology 4 807-818.
3. Barnes PJ 2008 Role of HDAC2 in the pathophysiology of COPD. Annual Reviews in Physiology 71 451-464.
4. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarelle-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J et al. 2006 Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes and Development 20 2871-2886. (Pubitemid 44771748)
5. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C & Maitra A 2007 Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. Journal of Nanobiotechnology 5 1-18.
6. Cao J, Liu Y, Jia L, Zhou HM, Kong Y, Yang G, Jiang LP, Li QJ & Zhong LF 2007 Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radical Biology & Medicine 43 968-975. (Pubitemid 47223632)
7. Carroll CE, Ellersieck MR & Hyder SM 2008 Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause 15 570-574.
8. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R III, Li X & Safe S 2008 Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Research 68 5345-5354.
9. Chanson P & Salenave S 2008 Acromegaly. Orphanet Journal of Rare Diseases 3 17.
10. Corson TW & Crews CM 2007 Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130 769-774.
11. Davis JR, Farrell WE & Clayton RN 2001 Pituitary tumours. Reproduction 121 363-371.
12. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V & Kurzrock R 2008 Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical Cancer Research 14 4491-4499.
13. Dujic J, Kippenberger S, Ramirez-Bosca A, Diaz-Alperi J, Bereiter-Hahn J, Kaufmann R, Bernd A & Hofmann M 2008 Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model. International Journal of Cancer 124 1422-1428.
14. Ezzat S & Asa SL 2006 Mechanisms of disease: the pathogenesis of pituitary tumors. Nature Clinical Practice. Endocrinology and Metabolism 2 220-230.
15. Fitzpatrick FA & Wheeler R 2003 The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. International Immunopharmacology 3 1699-1714. (Pubitemid 37421260)
16. Gidding CE, Kellie SJ, Kamps WA & de Graaf SS 1999 Vincristine revisited. Critical Review in Oncology and Hematology 29 267-287.
17. Hatcher H, Planalp R, Cho J, Torti FM & Torti SV 2008 Curcumin: from ancient medicine to current clinical trials. Cellular and Molecular Life Sciences 65 1631-1652.
18. Johnson JJ & Mukhtar H 2007 Curcumin for chemoprevention of colon cancer. Cancer Letters 255 170-181.
19. Kunnumakkara AB, Anand P & Aggarwal BB 2008 Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters 269 199-225.
20. Mancini T, Casanueva FF & Giustina A 2008 Hyperprolactinemia and prolactinomas. Endocrinology and Metabolism Clinics of North America 37 67-99.
21. Miller M, Chen S, Woodliff J & Kansra S 2008 Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells. Endocrinology 149 4158-4167.
22. Newell-Price J, Bertagna X, Grossman AB & Nieman LK 2006 Cushing's syndrome. Lancet 367 1605-1617.
23. Pae HO, Jeong SO, Kim HS, Kim SH, Song YS, Kim SK, Chai KY & Chung HT 2008 Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kB activation in RAW264.7 macrophages activated with LPS. Molecular Nutrition & Food Research 52 1082-1091.
24. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST et al. 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. PNAS 100 1034-1039. (Pubitemid 36183950)
25. Park C, Kim GY, Kim GD, Choi BT, Park YM & Choi YH 2006 Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncology Reports 15 1225-1231.
26. Perez Castro C, Giacomini D, Carbia Nagashima A, Onofri C, Graciarena M, Kobayashi K, Paez-Pereda M, Renner U, Stalla GK & Arzt E 2003 Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of pituitary lactosomatotrophic GH3 cells. Endocrinology 144 693-700. (Pubitemid 36205243)
27. Quinn J, Fisher P, Capocasale R, Achuthanandam R, Kam M, Bugelski P & Hrebien L 2007 A statistical pattern recognition approach for determining cellular viability and lineage phenotype in cultured cells and murine bone marrow. Cytometry 71 612-624. (Pubitemid 47221724)
28. Renner U, Newton CJ, Pagotto U, Sauer J, Arzt E & Stalla GK 1995 Involvement of interleukin-1 and interleukin-1 receptor antagonist in rat pituitary cell growth regulation. Endocrinology 136 3186-3193.
29. Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A & Stalla GK 1998 Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 1368-1375. (Pubitemid 28496421)
30. Sa G & Das T 2008 Anti cancer effects of curcumin: cycle of life and death. Cell Division 3 14.
31. Sandur SK, Ichikawa H, Pandey MK, Kunnumakkara AB, Sung B, Sethi G & Aggarwal BB 2007 Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radical Biology & Medicine 43 568-580. (Pubitemid 47058232)
32. Shankar S, Ganapathy S, Chen Q & Srivastava RK 2008 Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Molecular Cancer 7 16. (Pubitemid 351298391)
33. Shishodia S, Chaturvedi MM & Aggarwal BB 2007 Role of curcumin in cancer therapy. Current Problems in Cancer 31 243-305.
34. Singh S 2007 From exotic spice to modern drug? Cell 130 765-768.
35. Srivastava RK, Chen Q, Siddiqui I, Sarva K & Shankar S 2007 Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle 6 2953-2961.
36. Stalla GK, Stalla J, von Werder K, Muller OA, Gerzer R, Hollt V & Jakobs KH 1989 Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 125 699-706. (Pubitemid 19205058)